My initial post was moderated for unsubstantiated information but this interview is freely available on YouTube and on Hotcopper post #34314084
Executive Series interview July 2018
Below is the question and answer regarding DEP, word for word (direct quotes):
Tom Piotrowski:
”So when you look out over the next 6 months, what are going to be the important milestones for Starpharma?”
Jackie Fairley: “On the DEP side of things, completion of our Phase 2 trial for Dep-Docetaxel.”
Oh dear. It’s now 6 months to go until 2023! Still no full results for Dep-Docetaxel. What does this say about the CEO?
DYOR
Oh dear ~ CEO Jackie Fairley
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.002(2.00%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $37.67K | 384.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 39723 | 3 |
View Market Depth
| Last trade - 12.35pm 03/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |